A phase II trial of stereotactic body radiotherapy with concurrent anti-PD1 treatment in metastatic melanoma: evaluation of clinical and immunologic response

被引：0
作者：
Katrien De Wolf
Vibeke Kruse
Nora Sundahl
Mireille van Gele
Ines Chevolet
Reinhart Speeckaert
Lieve Brochez
Piet Ost
机构：
[1] University Hospital Ghent,Department of Radiation
[2] University Hospital Ghent,Oncology
[3] University Hospital Ghent,Department of Medical Oncology
来源：
Journal of Translational Medicine | / 15卷
关键词：
Cancer immunotherapy; Stereotactic body radiotherapy; Metastatic melanoma; Biomarkers; Immune monitoring;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 34 条
  • [1] A phase II trial of stereotactic body radiotherapy with concurrent anti-PD1 treatment in metastatic melanoma: evaluation of clinical and immunologic response
    De Wolf, Katrien
    Kruse, Vibeke
    Sundahl, Nora
    van Gele, Mireille
    Chevolet, Ines
    Speeckaert, Reinhart
    Brochez, Lieve
    Ost, Piet
    JOURNAL OF TRANSLATIONAL MEDICINE, 2017, 15
  • [2] Anti-PD1 and anti-PD-L1 in the treatment of metastatic melanoma
    Simeone, Ester
    Grimaldi, Antonio M.
    Ascierto, Paolo A.
    MELANOMA MANAGEMENT, 2015, 2 (01) : 41 - 50
  • [3] Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma
    Lee, J. H.
    Long, G. V.
    Boyd, S.
    Lo, S.
    Menzies, A. M.
    Tembe, V.
    Guminski, A.
    Jakrot, V.
    Scolyer, R. A.
    Mann, G. J.
    Kefford, R. F.
    Carlino, M. S.
    Rizos, H.
    ANNALS OF ONCOLOGY, 2017, 28 (05) : 1130 - 1136
  • [4] Artificial Intelligence Estimates the Importance of Baseline Factors in Predicting Response to Anti-PD1 in Metastatic Melanoma
    Indini, Alice
    Di Guardo, Lorenza
    Cimminiello, Carolina
    De Braud, Filippo
    Del Vecchio, Michele
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2019, 42 (08): : 643 - 648
  • [5] TGF-β mRNA levels in circulating extracellular vesicles are associated with response to anti-PD1 treatment in metastatic melanoma
    Crucitta, Stefania
    Cucchiara, Federico
    Marconcini, Riccardo
    Bulleri, Alessandra
    Manacorda, Simona
    Capuano, Annalisa
    Cioni, Dania
    Nuzzo, Amedeo
    de Jonge, Evert
    Mathjissen, Ron H. J.
    Neri, Emanuele
    van Schaik, Ron H. N.
    Fogli, Stefano
    Danesi, Romano
    Del Re, Marzia
    FRONTIERS IN MOLECULAR BIOSCIENCES, 2024, 11
  • [6] Phase II Clinical Trial of Second Course of Stereotactic Body Radiotherapy for Spinal Metastases
    Ito, Kei
    Nakajima, Yujiro
    Taguchi, Kentaro
    Ogawa, Hiroaki
    Saito, Makoto
    Murofushi, Keiko Nemoto
    CANCERS, 2024, 16 (12)
  • [7] Pathway signatures derived from on-treatment tumor specimens predict response to anti-PD1 blockade in metastatic melanoma
    Du, Kuang
    Wei, Shiyou
    Wei, Zhi
    Frederick, Dennie T.
    Miao, Benchun
    Moll, Tabea
    Tian, Tian
    Sugarman, Eric
    Gabrilovich, Dmitry, I
    Sullivan, Ryan J.
    Liu, Lunxu
    Flaherty, Keith T.
    Boland, Genevieve M.
    Herlyn, Meenhard
    Zhang, Gao
    NATURE COMMUNICATIONS, 2021, 12 (01)
  • [8] Functional Gene Expression Signatures from On-Treatment Tumor Specimens Predict Anti-PD1 Blockade Response in Metastatic Melanoma
    Chen, Shuzhao
    Zhang, Limei
    Lin, Haocheng
    Liang, Yang
    Wang, Yun
    BIOMOLECULES, 2023, 13 (01)
  • [9] CT texture analysis as a predictor of favorable response to anti-PD1 monoclonal antibodies in metastatic skin melanoma
    Bonnin, Angele
    Durot, Carole
    Barat, Maxime
    Djelouah, Manel
    Grange, Florent
    Mule, Sebastien
    Soyer, Philippe
    Hoeffel, Christine
    DIAGNOSTIC AND INTERVENTIONAL IMAGING, 2022, 103 (02) : 97 - 102
  • [10] Circulating Tumor DNA Early Kinetics Predict Response of Metastatic Melanoma to Anti-PD1 Immunotherapy: Validation Study
    Herbreteau, Guillaume
    Vallee, Audrey
    Knol, Anne-Chantal
    Theoleyre, Sandrine
    Quereux, Gaelle
    Varey, Emilie
    Khammari, Amir
    Dreno, Brigitte
    Denis, Marc G.
    CANCERS, 2021, 13 (08)
1234